about
Role of Education in HIV Clinical Outcomes in a Tuberculosis Endemic SettingHIV, tuberculosis, and noncommunicable diseases: what is known about the costs, effects, and cost-effectiveness of integrated care?Implementation of adolescent-friendly voluntary medical male circumcision using a school based recruitment program in rural KwaZulu-Natal, South Africa.HIV-Associated Tuberculosis.Individualised motivational counselling to enhance adherence to antiretroviral therapy is not superior to didactic counselling in South African patients: findings of the CAPRISA 058 randomised controlled trialClofazimine in the treatment of extensively drug-resistant tuberculosis with HIV coinfection in South Africa: a retrospective cohort study.Determinants of optimal adherence over time to antiretroviral therapy amongst HIV positive adults in South Africa: a longitudinal study.Timing of initiation of antiretroviral drugs during tuberculosis therapy.Initiating antiretrovirals during tuberculosis treatment: a drug safety review.Factors affecting first-month adherence to antiretroviral therapy among HIV-positive adults in South AfricaClinical evaluation of the OneStep Gonorrhea RapiCard InstaTest for detection of Neisseria gonorrhoeae in symptomatic patients from KwaZulu-Natal, South AfricaA qualitative study of patient motivation to adhere to combination antiretroviral therapy in South AfricaIntegration of antiretroviral therapy with tuberculosis treatment.Aetiology, clinical presentation, and outcome of meningitis in patients coinfected with human immunodeficiency virus and tuberculosis.Cost-Effectiveness of Initiating Antiretroviral Therapy at Different Points in TB Treatment in HIV-TB Coinfected Ambulatory Patients in South Africa.The immune reconstitution inflammatory syndrome after antiretroviral therapy initiation in patients with tuberculosis: findings from the SAPiT trial.Improved survival in multidrug-resistant tuberculosis patients receiving integrated tuberculosis and antiretroviral treatment in the SAPiT TrialWhen to start antiretroviral therapy during tuberculosis treatment?Effects of a reduced dose of stavudine on the incidence and severity of peripheral neuropathy in HIV-infected adults in South AfricaEmpirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomised controlled trialTuberculosis treatment outcomes among peri-urban children receiving doorstep tuberculosis care.The influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosisRatio of monocytes to lymphocytes in peripheral blood identifies adults at risk of incident tuberculosis among HIV-infected adults initiating antiretroviral therapy.High rates of tuberculosis in patients accessing HAART in rural South Africa.Changes to antiretroviral drug regimens during integrated TB-HIV treatment: results of the SAPiT trialUnderstanding the Profile of Tuberculosis and Human Immunodeficiency Virus Coinfection: Insights from Expanded HIV Surveillance at a Tuberculosis Facility in Durban, South Africa.Primary HIV-1 Drug Resistant Minority Variants.Risk factors for early mortality on antiretroviral therapy in advanced HIV-infected adults.Implementing isoniazid preventive therapy in a tuberculosis treatment-experienced cohort on ART.Effect of rifampicin and efavirenz on moxifloxacin concentrations when co-administered in patients with drug-susceptible TB.A Review of Moxifloxacin for the Treatment of Drug-Susceptible Tuberculosis.Implementation and Operational Research: Clinical Impact of the Xpert MTB/RIF Assay in Patients With Multidrug-Resistant Tuberculosis.Assessing Adherence to Antiretroviral Therapy in a Rural Paediatric Cohort in KwaZulu-Natal, South Africa.Detecting Mycobacterium tuberculosis using the loop-mediated isothermal amplification test in South Africa.High mortality rates in men initiated on anti-retroviral treatment in KwaZulu-Natal, South Africa.Hyperbilirubinemia in atazanavir-treated human immunodeficiency virus-infected patients: the impact of the UGT1A1*28 allele.Interleukin 1-Beta (IL-1β) Production by Innate Cells Following TLR Stimulation Correlates With TB Recurrence in ART-Treated HIV-Infected Patients.The Effect of Timing of Initiation of Antiretroviral Therapy on Loss to Follow-up in HIV-Tuberculosis Coinfected Patients in South Africa: An Open-Label, Randomized, Controlled Trial.Efavirenz dosing: influence of drug metabolizing enzyme polymorphisms and concurrent tuberculosis treatment.Plasma Cytokine Predictors of Tuberculosis Recurrence in Antiretroviral-Treated Human Immunodeficiency Virus-infected Individuals from Durban, South Africa.
P50
Q25017374-9D55BDC9-0BFC-42B2-9A1C-67507839635FQ27010874-3AB61EBA-E860-497D-A2E3-107C56F0CE96Q33560610-53C7F75F-D10C-4D54-84CE-6A93A3C73787Q34143510-79A1D40A-1C6B-4610-A11F-961954F927D1Q34288207-0F8DB009-1062-45B1-B609-DB18112473FEQ34331039-920CB713-80A8-4BB5-B130-5661AAF27075Q34664516-D35FD608-47E0-446F-9E18-84DC065C1F8EQ34790184-6C8562D9-942F-45CC-B24E-70508E50899CQ35043048-DA22325C-9E25-463D-A6CC-DAAA86B04324Q35109881-19CD7C55-BF50-47A2-BDCB-8980ABC03127Q35193222-987BE415-CEBC-4070-9B02-A70752CDF619Q35540921-6F654659-641E-4901-9541-F8A1178522E7Q35600960-EFF5D765-29DD-40E8-92A8-146D4027744BQ35634830-D31EE265-B365-4DF9-B002-A4D66A4D4E8CQ35854983-D3DBE319-2739-4056-93D1-FBD232BCCE69Q36501447-2559A26C-0247-493B-8852-104BDC15E3A7Q36627292-94ADA480-D2A6-4927-AB80-965017BB14B0Q36739450-FD73EB12-A1D0-4C48-9446-F786D0DC0530Q36870758-276600F9-7691-4C46-8C49-D578BA2BE4F2Q37061089-CBE11791-3F7E-4D09-A38C-60A7C9215F6EQ37184505-63EDF3B8-AB01-4857-A639-8BAEDB101562Q37466856-6A28ABBC-15F4-4FF6-9EC2-AA54971F5EDEQ37520181-79F23FE0-76D7-44E7-8C07-E48ED3E145CAQ37619616-8165DBD6-6092-4A6F-B381-D771EE5BBC8BQ37699575-DB4E6C59-0FA2-4E1F-86DA-1DE61E60CCC1Q37731301-B7A9A562-678D-4CEA-9915-950FB9ED12FCQ38373371-902F3B6C-557B-4A0B-A725-0BD63687445BQ38662366-8D59D4A7-205C-41FF-955B-2BACCB2FD549Q38841837-6B5FD132-8A82-44E2-B11C-8C271EE0CC07Q38973113-ABB3113A-B4E7-4CFC-9545-BA24423DD6D9Q39456569-4FBFF384-6187-4660-BC54-073543FB9833Q39504280-83E5002E-7B21-4441-9426-9AFA9E51D652Q39690844-9F9F9A81-F838-459E-99B3-36C33898A72FQ40040582-671ADDE9-DA03-4B01-9F17-2E560D8D267AQ40048922-427DC73B-90A7-4016-83A6-7D300A5DABE6Q40052062-8A3DB56A-6B80-4361-8FA9-96B564F31A6BQ40532007-58FEABC0-529E-443E-9F55-4FF533053FFBQ40750333-7430386B-7F99-4E24-8EEC-4193966EE32CQ41700252-61FFBEC1-8A1D-4A2C-A566-7C2AE67ADD43Q41920055-D0089E99-1DD6-4E0A-ACA7-A72681E708A2
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Kogieleum Naidoo
@ast
Kogieleum Naidoo
@en
Kogieleum Naidoo
@es
Kogieleum Naidoo
@nl
Kogieleum Naidoo
@sl
type
label
Kogieleum Naidoo
@ast
Kogieleum Naidoo
@en
Kogieleum Naidoo
@es
Kogieleum Naidoo
@nl
Kogieleum Naidoo
@sl
prefLabel
Kogieleum Naidoo
@ast
Kogieleum Naidoo
@en
Kogieleum Naidoo
@es
Kogieleum Naidoo
@nl
Kogieleum Naidoo
@sl
P106
P1153
35325100900
P31
P496
0000-0002-8874-6661